Literature DB >> 7935394

Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle.

Y Chen1, P L Chen, W H Lee.   

Abstract

Inactivation of both alleles of the p53 gene is commonly found in human cancers. In contrast to mutations of the retinoblastoma gene, certain altered forms of p53 gain growth-promoting functions. To explore the mechanisms underlying this gain of function, we have identified two nuclear proteins, with molecular masses of 42 and 38 kDa, respectively, that are specifically associated with p53 mutated within the simian virus 40 T-antigen-binding domain, "hot spots" found in many human tumors. These mutants transactivate the multiple-drug resistance gene promoter and cause cells to grow to higher density. Both the mutated p53 complex with p42 and p38 increase when cells enter S phase of the cell cycle but decrease in G1 and M phases, suggesting that they may have a role in promoting cell growth.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7935394      PMCID: PMC359207          DOI: 10.1128/mcb.14.10.6764-6772.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  74 in total

1.  A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization.

Authors:  H W Stürzbecher; R Brain; C Addison; K Rudge; M Remm; M Grimaldi; E Keenan; J R Jenkins
Journal:  Oncogene       Date:  1992-08       Impact factor: 9.867

2.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

3.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

4.  Wild-type p53 activates transcription in vitro.

Authors:  G Farmer; J Bargonetti; H Zhu; P Friedman; R Prywes; C Prives
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

5.  Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element.

Authors:  G P Zambetti; J Bargonetti; K Walker; C Prives; A J Levine
Journal:  Genes Dev       Date:  1992-07       Impact factor: 11.361

Review 6.  Glutathione transferases and cancer.

Authors:  S Tsuchida; K Sato
Journal:  Crit Rev Biochem Mol Biol       Date:  1992       Impact factor: 8.250

7.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

Authors:  M B Kastan; Q Zhan; W S el-Deiry; F Carrier; T Jacks; W V Walsh; B S Plunkett; B Vogelstein; A J Fornace
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

9.  Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest.

Authors:  Y Barak; M Oren
Journal:  EMBO J       Date:  1992-06       Impact factor: 11.598

10.  p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.

Authors:  T Unger; M M Nau; S Segal; J D Minna
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

View more
  6 in total

1.  p53 DNA binding can be modulated by factors that alter the conformational equilibrium.

Authors:  K G McLure; P W Lee
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

2.  Transforming growth factor β1 (TGF-β1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53.

Authors:  Gang Chen; Paritosh Ghosh; Thomas O'Farrell; Rachel Munk; Louis J Rezanka; Carl Y Sasaki; Dan L Longo
Journal:  J Biol Chem       Date:  2012-05-23       Impact factor: 5.157

3.  Tumor-derived p53 mutants induce NF-kappaB2 gene expression.

Authors:  Mariano J Scian; Katherine E R Stagliano; Michelle A E Anderson; Sajida Hassan; Melissa Bowman; Mike F Miles; Swati Palit Deb; Sumitra Deb
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

4.  Ectopic expression of cdc2/cdc28 kinase subunit Homo sapiens 1 uncouples cyclin B metabolism from the mitotic spindle cell cycle checkpoint.

Authors:  M L Hixon; A I Flores; M W Wagner; A Gualberto
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

5.  Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain.

Authors:  M W Frazier; X He; J Wang; Z Gu; J L Cleveland; G P Zambetti
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

6.  Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.

Authors:  Ken H Young; Karen Leroy; Michael B Møller; Gisele W B Colleoni; Margarita Sánchez-Beato; Fábio R Kerbauy; Corinne Haioun; Jens C Eickhoff; Allen H Young; Philippe Gaulard; Miguel A Piris; Terry D Oberley; William M Rehrauer; Brad S Kahl; James S Malter; Elias Campo; Jan Delabie; Randy D Gascoyne; Andreas Rosenwald; Lisa Rimsza; James Huang; Rita M Braziel; Elaine S Jaffe; Wyndham H Wilson; Louis M Staudt; Julie M Vose; Wing C Chan; Dennis D Weisenburger; Timothy C Greiner
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.